Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidines

Raja Nhili, Paul Peixoto, Sabine Depauw, Sébastien Flajollet, Xavier Dezitter, Manoj M. Munde, Mohamed A. Ismail, Arvind Kumar, Abdelbasset A. Farahat, Chad E. Stephens, Martine Duterque-Coquillaud, W. David Wilson, David W. Boykin, Marie Hélène David-Cordonnier

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Direct modulation of gene expression by targeting oncogenic transcription factors is a new area of research for cancer treatment. ERG, an ETS-family transcription factor, is commonly over-expressed or translocated in leukaemia and prostate carcinoma. In this work, we selected the di-(thiophene-phenyl- amidine) compound DB1255 as an ERG/DNA binding inhibitor using a screening test of synthetic inhibitors of the ERG/DNA interaction followed by electrophoretic mobility shift assays (EMSA) validation. Spectrometry, footprint and biosensor-surface plasmon resonance analyses of the DB1255/DNA interaction evidenced sequence selectivity and groove binding as dimer. Additional EMSA evidenced the precise DNA-binding sequence required for optimal DB1255/DNA binding and thus for an efficient ERG/DNA complex inhibition. We further highlighted the structure activity relationships from comparison with derivatives. In cellulo luciferase assay confirmed this modulation both with the constructed optimal sequences and the Osteopontin promoter known to be regulated by ERG and which ERG-binding site was protected from DNaseI digestion on binding of DB1255. These data showed for the first time the ERG/DNA complex modulation, both in vitro and in cells, by a heterocyclic diamidine that specifically targets a portion of the ERG DNA recognition site.

Original languageEnglish (US)
Pages (from-to)125-138
Number of pages14
JournalNucleic Acids Research
Volume41
Issue number1
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Pentamidine
Human Activities
Transcription Factors
DNA
Electrophoretic Mobility Shift Assay
Amidines
Thiophenes
Osteopontin
Gene Targeting
Surface Plasmon Resonance
Biosensing Techniques
Structure-Activity Relationship
Luciferases
Prostate
Digestion
Spectrum Analysis
Leukemia
Binding Sites
Carcinoma
Gene Expression

ASJC Scopus subject areas

  • Genetics

Cite this

Nhili, R., Peixoto, P., Depauw, S., Flajollet, S., Dezitter, X., Munde, M. M., ... David-Cordonnier, M. H. (2013). Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidines. Nucleic Acids Research, 41(1), 125-138. https://doi.org/10.1093/nar/gks971

Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidines. / Nhili, Raja; Peixoto, Paul; Depauw, Sabine; Flajollet, Sébastien; Dezitter, Xavier; Munde, Manoj M.; Ismail, Mohamed A.; Kumar, Arvind; Farahat, Abdelbasset A.; Stephens, Chad E.; Duterque-Coquillaud, Martine; David Wilson, W.; Boykin, David W.; David-Cordonnier, Marie Hélène.

In: Nucleic Acids Research, Vol. 41, No. 1, 01.01.2013, p. 125-138.

Research output: Contribution to journalArticle

Nhili, R, Peixoto, P, Depauw, S, Flajollet, S, Dezitter, X, Munde, MM, Ismail, MA, Kumar, A, Farahat, AA, Stephens, CE, Duterque-Coquillaud, M, David Wilson, W, Boykin, DW & David-Cordonnier, MH 2013, 'Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidines', Nucleic Acids Research, vol. 41, no. 1, pp. 125-138. https://doi.org/10.1093/nar/gks971
Nhili, Raja ; Peixoto, Paul ; Depauw, Sabine ; Flajollet, Sébastien ; Dezitter, Xavier ; Munde, Manoj M. ; Ismail, Mohamed A. ; Kumar, Arvind ; Farahat, Abdelbasset A. ; Stephens, Chad E. ; Duterque-Coquillaud, Martine ; David Wilson, W. ; Boykin, David W. ; David-Cordonnier, Marie Hélène. / Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidines. In: Nucleic Acids Research. 2013 ; Vol. 41, No. 1. pp. 125-138.
@article{a0e1157b8ac749c6a489b9c111588b48,
title = "Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidines",
abstract = "Direct modulation of gene expression by targeting oncogenic transcription factors is a new area of research for cancer treatment. ERG, an ETS-family transcription factor, is commonly over-expressed or translocated in leukaemia and prostate carcinoma. In this work, we selected the di-(thiophene-phenyl- amidine) compound DB1255 as an ERG/DNA binding inhibitor using a screening test of synthetic inhibitors of the ERG/DNA interaction followed by electrophoretic mobility shift assays (EMSA) validation. Spectrometry, footprint and biosensor-surface plasmon resonance analyses of the DB1255/DNA interaction evidenced sequence selectivity and groove binding as dimer. Additional EMSA evidenced the precise DNA-binding sequence required for optimal DB1255/DNA binding and thus for an efficient ERG/DNA complex inhibition. We further highlighted the structure activity relationships from comparison with derivatives. In cellulo luciferase assay confirmed this modulation both with the constructed optimal sequences and the Osteopontin promoter known to be regulated by ERG and which ERG-binding site was protected from DNaseI digestion on binding of DB1255. These data showed for the first time the ERG/DNA complex modulation, both in vitro and in cells, by a heterocyclic diamidine that specifically targets a portion of the ERG DNA recognition site.",
author = "Raja Nhili and Paul Peixoto and Sabine Depauw and S{\'e}bastien Flajollet and Xavier Dezitter and Munde, {Manoj M.} and Ismail, {Mohamed A.} and Arvind Kumar and Farahat, {Abdelbasset A.} and Stephens, {Chad E.} and Martine Duterque-Coquillaud and {David Wilson}, W. and Boykin, {David W.} and David-Cordonnier, {Marie H{\'e}l{\`e}ne}",
year = "2013",
month = "1",
day = "1",
doi = "10.1093/nar/gks971",
language = "English (US)",
volume = "41",
pages = "125--138",
journal = "Nucleic Acids Research",
issn = "0305-1048",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidines

AU - Nhili, Raja

AU - Peixoto, Paul

AU - Depauw, Sabine

AU - Flajollet, Sébastien

AU - Dezitter, Xavier

AU - Munde, Manoj M.

AU - Ismail, Mohamed A.

AU - Kumar, Arvind

AU - Farahat, Abdelbasset A.

AU - Stephens, Chad E.

AU - Duterque-Coquillaud, Martine

AU - David Wilson, W.

AU - Boykin, David W.

AU - David-Cordonnier, Marie Hélène

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Direct modulation of gene expression by targeting oncogenic transcription factors is a new area of research for cancer treatment. ERG, an ETS-family transcription factor, is commonly over-expressed or translocated in leukaemia and prostate carcinoma. In this work, we selected the di-(thiophene-phenyl- amidine) compound DB1255 as an ERG/DNA binding inhibitor using a screening test of synthetic inhibitors of the ERG/DNA interaction followed by electrophoretic mobility shift assays (EMSA) validation. Spectrometry, footprint and biosensor-surface plasmon resonance analyses of the DB1255/DNA interaction evidenced sequence selectivity and groove binding as dimer. Additional EMSA evidenced the precise DNA-binding sequence required for optimal DB1255/DNA binding and thus for an efficient ERG/DNA complex inhibition. We further highlighted the structure activity relationships from comparison with derivatives. In cellulo luciferase assay confirmed this modulation both with the constructed optimal sequences and the Osteopontin promoter known to be regulated by ERG and which ERG-binding site was protected from DNaseI digestion on binding of DB1255. These data showed for the first time the ERG/DNA complex modulation, both in vitro and in cells, by a heterocyclic diamidine that specifically targets a portion of the ERG DNA recognition site.

AB - Direct modulation of gene expression by targeting oncogenic transcription factors is a new area of research for cancer treatment. ERG, an ETS-family transcription factor, is commonly over-expressed or translocated in leukaemia and prostate carcinoma. In this work, we selected the di-(thiophene-phenyl- amidine) compound DB1255 as an ERG/DNA binding inhibitor using a screening test of synthetic inhibitors of the ERG/DNA interaction followed by electrophoretic mobility shift assays (EMSA) validation. Spectrometry, footprint and biosensor-surface plasmon resonance analyses of the DB1255/DNA interaction evidenced sequence selectivity and groove binding as dimer. Additional EMSA evidenced the precise DNA-binding sequence required for optimal DB1255/DNA binding and thus for an efficient ERG/DNA complex inhibition. We further highlighted the structure activity relationships from comparison with derivatives. In cellulo luciferase assay confirmed this modulation both with the constructed optimal sequences and the Osteopontin promoter known to be regulated by ERG and which ERG-binding site was protected from DNaseI digestion on binding of DB1255. These data showed for the first time the ERG/DNA complex modulation, both in vitro and in cells, by a heterocyclic diamidine that specifically targets a portion of the ERG DNA recognition site.

UR - http://www.scopus.com/inward/record.url?scp=84871748962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871748962&partnerID=8YFLogxK

U2 - 10.1093/nar/gks971

DO - 10.1093/nar/gks971

M3 - Article

C2 - 23093599

AN - SCOPUS:84871748962

VL - 41

SP - 125

EP - 138

JO - Nucleic Acids Research

JF - Nucleic Acids Research

SN - 0305-1048

IS - 1

ER -